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Abstract
Background: CD56
+ T cells are abundant in liver and play an important role in host innate immunity against viral infections,
including hepatitis C virus (HCV) infection, a common infection among heroin abusers. We thus investigated the in vivo
impact of heroin use or heroin use plus HCV infection on the CD56
+ T cell frequency and function.
Methodology/Principal Findings: A total of 37 heroin users with (17) or without (20) HCV infection and 17 healthy
subjects were included in the study. Although there was no significant difference in CD56
+ T cell frequency in PBMCs
among three study groups, CD56
+ T cells isolated from the heroin users had significantly lower levels of constitutive
interferon-gamma (IFN-c) expression than those from the normal subjects. In addition, when stimulated by interleukin (IL)-
12, CD56
+ natural T cells from HCV-infected heroin users produced significantly lower levels of IFN-c than those from the
normal subjects. This diminished ability to produce IFN-c by CD56
+ T cells was associated with the increased plasma HCV
viral loads in the HCV-infected heroin users. Investigation of the mechanisms showed that although heroin use or heroin
use plus HCV infection had little impact on the expression of the key positive regulators (IL-12 receptors, STAT-1, 3, 4, 5,
JAK-2, and TYK-2) in IL-12 pathway, heroin use or heroin use plus HCV infection induced the expression of suppressor of
cytokine signaling protein-3 (SOCS-3) and protein inhibitors of activated STAT-3 (PIAS-3), two key inhibitors of IL-12
pathway.
Conclusion/Significance: These findings provide compelling in vivo evidence that heroin use or heroin use plus HCV
infection impairs CD56
+ T cell-mediated innate immune function, which may account for HCV infection and persistence in
liver.
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Introduction
H e p a t i t i sCv i r u s( H C V )h a sn o wb e e nr e c o g n i z e da sam a j o r
public health problem worldwide. HCV infection is a significant
cause of chronic liver disease, with frequent progression to
cirrhosis and an elevated risk for the development of
hepatocellular carcinoma. In the United States, about 15–30%
of all HIV-infected persons are also infected with HCV. Since
the use of highly active antiretroviral therapy in 1996, HCV-
related liver disease has now emerged as a major cause of
morbidity and mortality among HIV-infected patients. HCV
infection is extremely common among injection heroin users
[1,2,3,4,5,6]. Rates of HCV infection among past and current
injection drug users are extremely high generally ranging from
70 to over 90% (antibody positive for HCV) in the United States
[7,8,9,10]. Drug abuse, especiallyt h ea b u s eo fh e r o i n ,t h em o s t
commonly used opiate, is a significant risk factor for HCV
infection and the development of chronic HCV disease
[1,2,3,4,5,6].
The negative impact of drug abuse on host immune system
has been currently considered as an important factor in
increasing the likelihood for HCV infection and the development
of chronic HCV disease in drug abuse population. Opioid drugs,
such as heroin and morphine, have been demonstrated to impair
the immune system [11,12,13] and facilitate HCV replication in
human hepatocytes [14,15]. Opioids alter immune system by
acting directly on immune cells, possibly via opioid receptor on
the surface of immune cells [16]. Opioids exert profound
influence on function of the immune cells, including T cells, B
cells, monocytes, and NK cells. Opioids have been shown to
inhibit the expression of antiviral cytokines, including interferon
(IFN)- a/b and IFN-c in PBMCs [17,18], in T cells [19] and
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as heroin suppress CD56
+ T cell-mediated innate immunity
against HCV infection. Since CD56
+ T cells are abundant in
liver and are a key member of host innate immune cell family in
protecting liver from viral infections, the impairment of CD56
+
T cell-mediated innate immunity may account for HCV
infection and persistence in liver.
CD56
+ T cells express both natural killer (NK) and T cell
markers (CD56 and CD3, respectively) and functionally
display properties of both NK cells and T cells [21,22]. A
normal human liver, as the primary site of HCV infection,
contains lymphocytes that are enriched for CD56
+ T cells
[23,24]. CD56
+ T cells possess the ability to rapidly produce
large quantities of both Th1 and Th2 cytokines, particularly
IFN-c, tumor necrosis factor-a,i n t e r l e u k i n ( I L )- 2 ,I L - 4 ,a n d
IL-13 without need for priming or clonal expansion
[22,23,25,26,27,28]. This ability of CD56
+ T cells permits
them to play a key role in the communications between the
innate and adaptive immune cells. CD56
+ T cells alongside
NK cells as well as NKT cells have been considered as
frontline innate immune effectors and potential regulators for
both innate and adaptive immune responses against microor-
ganisms including viruses [24,29,30]. More importantly, recent
studies have highlighted that CD56
+ T cells play an important
role in determining the outcome of acute HCV infection [31],
and are known to be depleted in the livers of patients with
chronic HCV infection [31,32,33,34]. Our recent study [35]
also showed that CD56
+ T cells have the ability to inhibit
HCV replication in human hepatocytes in vitro.
S i n c et h el i v e rc o n t a i n sal a r g en u m b e ro fC D 5 6
+ T cells
[23,24], an important question is why CD56
+ T cells in liver
fail to protect hepatocytes from HCV infection and eliminate
the virus in the liver. One speculation is that heroin use or
heroin use plus HCV infection impair CD56
+ T cell-mediated
antiviral function. It is known that HCV has ability to escape
and counteract host innate immunity. In addition, drugs of use,
such as heroin, have been shown to suppress the host immune
system. In the present study, we investigated the frequency and
antiviral function of circulating CD56
+ T cells isolated from
the heroin users with or without HCV infection. We also
examined the mechanisms underlying the impact of heroin use
or heroin use plus HCV infection on the antiviral function of
CD56
+ T cells.
Results
1. Effect of Heroin Use/HCV Infection on CD56
+ T Cell
Frequency in PBMCs
We first examined the frequency of CD56
+ T cells in peripheral
blood mononuclear cells (PBMCs) of the heroin users with or
without HCV infection compared with that of the healthy subjects.
CD56
+ T cells were isolated from PBMCs by CD3
+CD56
+ T Cell
Isolation Kit (Miltenyi Biotec, Auburn, CA) (Fig. 1). The
percentages of CD56
+ T cells in PBMCs from three study groups
are shown in Fig. 2A. The frequency of circulating CD56
+ T cells
was 3.87% (median, ranging from 1.37%–8.94%) in PBMCs from
the healthy subjects. Similar frequency was observed in the heroin
users with (median 3.78%, ranging from 1.2%–10.8%) or without
(median 3.8%, ranging from 1.11%–9.09%) HCV infection.
Statistically, there were no significant differences in the percentage
of CD56
+ T cells in PBMCs among the three study groups
(P.0.05).
2. Effect of Heroin Use or Heroin Use plus HCV Infection
on IFN-c Expression by CD56
+ T Cells
Since IFN-c is the major component responsible for the CD56
+
T cell-mediated antiviral action [35], we investigated whether
heroin use or heroin use plus HCV infection affect IFN-c
expression in CD56
+ T cells. As shown in Fig. 2B, freshly isolated
CD56
+ T cells from the heroin users, either with or without HCV
infection, had significantly lower levels of IFN-c mRNA than those
from the healthy subjects. However, there was no difference
between the heroin users with HCV infection and those without
HCV infection (Fig. 2B). To further determine the functional
capacity of CD56
+ T cells in the heroin users with or without
HCV infection and the control subjects, we assessed the ability of
IL-12-stimulated CD56
+ T cells to produce IFN-c. IL-12 plays a
key role in the induction of IFN-c by the immune cells including
CD56
+ T cells [36,37]. When stimulated by IL-12, CD56
+ T cells
from HCV-infected heroin users produced significantly lower
levels of IFN-c at both mRNA (Fig. 3A) and protein (Fig. 3B) levels
than those from the healthy subjects. However, although IL-12-
activated CD56
+ T cells from the heroin users without HCV
infection also produced lower levels of IFN-c at both mRNA
(Fig. 3A) and protein (Fig. 3B) levels than those from the healthy
subjects, these differences were not statistically significant
(P=0.1849 and P=0.175, respectively) (Fig. 3). This impaired
Figure 1. Isolation of CD56
+ T and CD56
- T cells from PBMCs. The purity of enriched cell population was determined by flow cytometry using
antibodies to CD56 (PE) and CD3 (FITC) markers.
doi:10.1371/journal.pone.0009602.g001
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+ T cells from the heroin users
with or without HCV infection was confirmed by the observation
that CD56
+ T cells from those subjects had diminished ability to
inhibit HCV JFH-1 replication in human hepatocytes comparing
with the cells from the healthy subjects (Fig. 4A and 4B).
3. HCV Viral Loads Is Negatively Associated with IL-12-
Induced IFN-c Production
In order to further determine the negative impact of HCV
infection on CD56
+ T cells, we used linear regression analysis to
determine whether there is a correlation between the plasma viral
loads and the levels of IFN-c proteins produced in IL-12-activated
CD56
+ T cells from the HCV-infected heroin users. As shown in
Fig. 5, the plasma HCV viral loads is negatively associated with
the levels of IFN-c proteins produced by IL-12-stimulated CD56
+
T cells from the HCV-infected heroin users (Fig. 5).
4. Effect of Heroin Use or Heroin Use plus HCV Infection
on the Gene Expression of Key Elements and the
Suppressors (SOCSs and PIASs) in IL-12 Pathway
To investigate whether heroin use or heroin use plus HCV
infection has an impact on IL-12 pathway in CD56
+ T cells, the
transcriptional expression of key elements [IL-12 receptors, signal
transducer and activator of transcription (STAT)-1, 3, 4, 5, janus
kinase (JAK)-2, and tyrosine kinase (TYK)-2] in IL-12 pathway in
CD56
+ T cells was analyzed by the real-time RT PCR. The
Figure 2. Effect of heroin use or heroin use plus HCV infection on CD56
+ T cells. (A) Heroin use or heroin use plus HCV infection has little
impact on CD56
+ T cell frequency (%) in PBMCs. The CD56
+ T cell frequency (%) in PBMCs from healthy subjects (n=17), heroin users with (n=17) or
without (n=20) HCV infection were shown by scatter plots. Median values are indicated by horizontal bars. Statistical significance was calculated by
the Mann-Whitney U-test. There is no significant difference in CD56
+ T cell numbers in PBMCs between normal subjects, heroin users with or without
HCV infection (P.0.05). (B) Heroin use down-regulates IFN-c gene expression in unstimulated CD56
+ T cells. CD56
+ T cells were isolated from healthy
subjects (n=17) and heroin users with (n=17) or without (n=20) HCV infection. Total cellular RNA extracted from freshly isolated CD56
+ T cells was
subjected to the real-time RT PCR for IFN-c and GAPDH mRNA quantification. The data are expressed as the relative ratio of the IFN-c mRNA levels to
GAPDH mRNA levels. Median values are indicated by horizontal bars and statistical significance was calculated by the Mann-Whitney U-test.
doi:10.1371/journal.pone.0009602.g002
Figure 3. Heroin use or heroin use plus HCV infection down-regulate IFN-c expression in IL-12-stimulated CD56
+ T cells. CD56
+ T cells
isolated from the healthy subjects (n=17) and the heroin users with (n=17) or without (n=20) HCV infection were stimulated by IL-12 in vitro for
48 h. (A) Total cellular RNA extracted from IL-12-stimulated CD56
+ T cells was subjected to the real-time RT PCR for the mRNA levels of IFN-c and
GAPDH. The data are expressed as the relative ratio of the IFN-c to GAPDH mRNA levels. Mean values are indicated by horizontal bars and statistical
significance was calculated by the Mann-Whitney U-test. (B) IFN-c protein levels in IL-12-stimulated CD56
+ T cell cultures were determined by ELISA.
Median values are indicated by horizontal bars and statistical significance was calculated by the Mann-Whitney U-test.
doi:10.1371/journal.pone.0009602.g003
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+ T
cells were correlated to GAPDH mRNA and there was no
difference in the expression patterns of these mRNAs between
normal subjects, heroin users with HCV infection, and heroin
users without HCV infection (P.0.05) (Fig. 6). To further
determine the mechanism(s) involved in heroin use- or heroin
use plus HCV infection-mediated dysfunction of CD56
+ T cells,
we examined whether heroin use or heroin use plus HCV
infection was associated with the induction of intracellular
suppressors of IL-12 signaling pathway. Among the suppressor
members [suppressors of cytokine signaling (SOCS)-1, 2, and 3,
protein inhibitors of activated STAT (PIAS)-1, 3, x, and y] tested,
SOCS-3 levels, were elevated in CD56
+ T cells freshly isolated
from the heroin users with or without HCV infection (Fig. 7). In
addition, CD56
+ T cells freshly isolated from the HCV-infected
heroin users had significantly higher levels of PIAS-3 than those
from the healthy subjects (Fig. 7). Although there was an increase
in PIAS-3 levels in CD56
+ T cells from the heroin users without
HCV infection, this difference was not statistically significant
(Fig. 7). In addition, there was no significant difference in the
expression of SOCS-3 and PIAS-3 between the heroin users
without HCV infection and the heroin users with HCV infection
(Fig. 7). Knowing that SOCS-3 and PIAS-3 were affected by
heroin use or heroin use plus HCV infection, we further examined
whether the expression of these two factors were associated with
HCV viral loads. There was no association between the levels of
SOCS-3 and HCV viral loads (Fig. 8). However, there is a positive
association (P=0.0226) between PIAS-3 and HCV viral loads
(Fig. 8).
Discussion
In this study, we investigated the impact of heroin use or heroin
use plus HCV infection on the antiviral functions of CD56
+ T
cells. As demonstrated in our earlier study [35], CD56
+ T cells
have the ability to inhibit HCV replication in human hepatocytes.
This IFN-c-mediated anti-HCV ability of CD56
+ T cells,
however, was impaired by heroin use or heroin use plus HCV
infection (Fig. 4). We demonstrated that although there was no
significant difference in CD56
+ T cell frequency in PBMCs,
CD56
+ T cells from the heroin users with or without HCV
infection had impaired ability to produce IFN-c (Fig. 2). Despite of
the limitation of lacking HCV-infected non-heroin group as a
control, our study has shown that HCV infection was involved in
the impairment of CD56
+ T cell function, as we showed that when
Figure 4. Comparison of anti-HCV activity of CD56
+ T cells among three study groups. HCV JFH-1-infected Huh 7 cells (day 3 post
infection) were cultured for 48h in the presence or absence of pooled SN from IL-12-stimulated CD56
+ T cells from the healthy subjects and the
heroin users with or without HCV infection as indicated. (A) Real-time RT-PCR analysis of HCV RNA. Total cellular RNA extracted from Huh7 cells
treated with or without pooled SN of CD56
+ T cells from three study groups as indicated was analyzed by the real-time RT-PCR for HCV and GAPDH
RNA quantification. The data are expressed as HCV RNA levels relative (%) to control (without SN treatment, which is defined as 100). The results are
mean 6SD of triplicate cultures, representative of three repeated experiments using pooled CD56
+ T SN from three study groups. Statistical
significance was performed using student t-test. (B) Immunofluoresence analysis of HCV NS3 protein expression in Huh 7 cells. HCV NS3 protein
expression in Huh7 cells treated with or without pooled CD56
+ T SN from three study groups as indicated was determined by immunofluoresence
staining with antibody against HCV NS3 (green). The nuclei were stained with Hoechst 33258 (blue). One representative result of 3 experiments is
shown (2006).
doi:10.1371/journal.pone.0009602.g004
Figure 5. Plasma HCV viral loads is negatively associated with
IFN-c produced by IL-12-stimulated CD56
+ T cells. Spearman
correlation (r and p-value) was calculated to determine the relationship
between the levels of IL-12-induced IFN-c protein by CD56
+ T cells and
the levels of HCV RNA in plasma from HCV-infected heroin users
(n=17). The levels of IFN-c protein produced by IL-12-stimulated CD56
+
T cells were negatively correlated with those of plasma HCV RNA
(P,0.01).
doi:10.1371/journal.pone.0009602.g005
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+ T cells were stimulated with IL-12, significant decrease of
CD56
+ T cell produced IFN-c was only observed in the HCV-
infected heroin users (Fig. 3). The negative impact of HCV
infection on CD56
+ T cell function was also observed in the
experiments showing that there is a negative association between
HCV viral loads and the levels of IFN-c produced by IL-12-
stimulated CD56+ T cells (Fig. 5). To investigate the mechanism(s)
underlying heroin use- or heroin use plus HCV infection-mediated
downregulation of IFN-c production in IL-12-stimulated CD56
+
T cells, we examined whether heroin use or heroin use plus HCV
infection have the impact on IL-12 pathway in CD56
+ T cells. IL-
12 is a central regulator that coordinates innate and adaptive
immune responses [37,38]. IL-12-mediated immune responses are
largely through its ability to drive IFN-c secretion. It is a potent
inducer of IFN-c from T, NK cells, as well as CD56
+ T cells and is
necessary for the development of Th1 response in most systems
[36,37]. Because IL-12 plays a central role in protection from
diverse intracellular pathogens, IL-12 has, itself, been shown to be
targeted by HCV [39]. IL-12 primarily signals through the JAK/
STAT pathway to induce IFN-c production (Fig. 9) [40]. IL-
12p40 and p35 are IL-12 subunits that bind to IL-12 receptor, IL-
12Rb1 and b2, respectively. The binding brings the associated
Jaks (Jak2 and Tyk2) phosphorylation and the activated signals are
then transduced to STATs, which become phosphorylated and
form dimers (Fig. 9). The STAT dimers shuttle into the nucleus
where they bind to STAT-binding sites in the IFN-c promoter and
induce expression of IFN-c gene (Fig. 9). We thus investigated
whether heroin use or heroin use plus HCV infection suppress the
expression of the key elements in JAK/STAT pathway. We first
examined the gene expression of IL-12 Rb1/b2 by CD56
+ T cells
isolated from the subjects of three groups. No significant
differences in IL-12Rb1/b2 expression were found among three
groups (Fig. 6). We then focused on the members (STAT-1, 3, 4,
and 5) of STAT family as well as JAK-2 and TYK-2, as the
activation of these factors results in the production of IFN-
c.However, there were no significant differences in the expression
of these positive regulators in CD56
+ T cells isolated from the
subjects of three groups (Fig. 6).
Figure 6. Effect of heroin use or heroin use plus HCV infection on the key element expression in IL-12 pathway. CD56
+ T cells
(unstimulated) were isolated from healthy subjects (n=17) and heroin users with (n=17) or without (n=20) HCV infection. Total cellular RNA
extracted from freshly isolated CD56
+ T cells was subjected to the real-time RT PCR for key element (IL-12Rb1, IL-12Rb2, STAT-1, 3, 4, 5, JAK-2, TYK-2)
in IL-12 pathway and GAPDH mRNA quantification. The data are expressed as the relative ratio of the key element mRNA level to GAPDH mRNA level.
Median values are indicated by horizontal bars and statistical significance was calculated by the Mann-Whitney U-test.
doi:10.1371/journal.pone.0009602.g006
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+ T cells
(unstimulated) were isolated from the healthy subjects (n=17), heroin users with (n=17) or without (n=20) HCV infection. Total cellular RNA
extracted from freshly isolated CD56
+ T was subjected to the real-time RT PCR for the suppressor and GAPDH mRNA quantification. The data are
expressed as the relative ratio of mRNA levels of suppressor (SOCS-1, 2, and 3, or PIAS-1, 3, x, and y) to those of GAPDH. Median values are indicated
by horizontal bars and statistical significance was calculated by the Mann-Whitney U-test.
doi:10.1371/journal.pone.0009602.g007
Figure 8. The relationship between plasma HCV viral loads and the levels of SOCS-3 and PIAS-3 in CD56
+ T cells. Spearman correlation
(r and p-value) was calculated to determine the relationship between the levels of SOCS-3/PIAS-3 in CD56
+ T cells and the levels of HCV RNA in plasma
from the heroinusers infected with HCV (n=17). Thelevelsof PIAS-3 in CD56
+ T cells were positively correlated with those of plasma HCV RNA (P,0.01).
doi:10.1371/journal.pone.0009602.g008
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heroin use plus HCV infection-mediated impairment of CD56
+ T
cell function, we attempted to determine whether heroin use or
heroin use plus HCV infection induce the expression of negative
regulators in IL-12 signaling pathway. Two suppressor families,
SOCSs and PIASs, have been identified as the negative regulators
in IL-12 signaling pathway [38,40,41,42,43] (Fig. 9). Among the
suppressor family members examined, the level of SOCS-3 gene
expression was elevated in CD56
+ T cells isolated from the heroin
users with or without HCV infection (Fig. 7). SOCS-3 has been
reported to be a negative regulator of IL-12 signaling by
preventing STAT-4 binding to the IL-12Rb2 subunit [42].
SOCS-3 and SOCS-1, another member of SOCS family, have
been shown to inhibit IFN-mediated antiviral activities [44] and
IFN signaling [45,46]. In addition to the mechanisms of SOCS
family, we also examined the impact of heroin use or heroin use
plus HCV infection on the expression of PIASs. The members of
PIAS are a special inhibitors of STATs that inhibit STAT-
mediated gene activation by blocking the DNA binding activity of
STATs [47,48]. PIAS members are also an important factors in
the IL-12-induced IFN-c production in peripheral blood T cells
[49,50]. We found that although heroin use or heroin use plus
HCV infection had little effects on the expression of PIAS-1,
PIAS-x and PIAS-y in CD56
+ T cells, the levels of PIAS-3 gene
expression in CD56
+ T cells from the HCV-infected heroin users
was significantly increased, comparing with the control subjects
(Fig. 7). This observation was further confirmed by the correlation
analyses, showing that there was a positive association between the
levels of PIAS-3 and HCV viral loads (Fig. 8). These findings
provide additional evidence to support the involvement of HCV
infection in the impairment of CD56
+ T cell function.
Taken together, the findings presented in this study provide
compelling ex vivo as well as in vivo evidence that heroin use or
heroin use plus HCV infection, through the induction of two
key suppressors (SOCS-3 and PIAS-3) in IL-12 pathway,
suppressed IFN-c production by CD56
+ Tc e l l s .T h i si m p a i r e d
ability of CD56
+ T cells to produce IFN-c was correlated with
increased levels of HCV RNA in plasma from the HCV-infected
heroin users. This in vivo finding is supported by our in vitro
observation [35] that CD56
+ T cells, through the secretion of
IFN-c that activates JAK/STAT pathway, inhibit HCV
replication in human hepatocytes. Since CD56
+ Tc e l l sa r e
abundant in liver and a key component of host innate immune
cell-mediated defense mechanisms, the impairment of CD56
+ T
cell function is likely to favor HCV infection and persistence in
liver. It is known that heroin addicts are a high-risk group for
HCV infection and the development of chronic HCV disease.
Thus, to understand the impact of opioids such as heroin on the
host immune system against HCV infection is of great interest
for developing intervention strategies to reconstitute the
immune system and to control viral replication in HCV-infected
heroin users.
Materials and Methods
Ethics Statement
The Institutional Review Boards at The University of
Pennsylvania School of Medicine approved this study, and written
informed consent was obtained from all the study subjects. All
investigations have been conducted according to the principles
expressed in the Declaration of Helsinki.
Study Population
Subjects addicted to heroin and admitted to the Clinic, The
Center for Studies of Addiction at University of Pennsylvania
School of Medicine, were recruited for this study. 37 heroin users
and 17 healthy subjects were recruited for this study. Out of 37
heroin users, 17 were infected with HCV. Subjects were excluded
if they had chronic systemic illness (cardiac, renal, pulmonary,
hepatic, endocrine, metabolic or autoimmune disorders), major
psychiatric disorders or if they were abusing other substrates other
than heroin. For women, pregnancy was also a reason for
exclusion. Control subjects were recruited using convenience
sampling from the community in which the study site was located.
Control subjects with no history of drug or alcohol abuse were also
Figure 9. Schematic diagram of possible molecular mecha-
nisms underlying heroin use/HCV infection-mediated suppres-
sion of IL-12 pathway. Although heroin use or heroin use plus HCV
infection has little impact on the gene expression of key elements (IL-
12Rb1, IL-12Rb2, STAT-1, 3, 4, 5, JAK-2, TYK-2) in IL-12 pathway in CD56
+
T cells. Heroin use or heroin use plus HCV infection induces the
expression of SOCS-3 or PIAS-3, the key negative regulators of IL-12
pathway, resulting in the downregulation of IL-12-mediated IFN-c
production.
doi:10.1371/journal.pone.0009602.g009
Table 1. Demographics of Study Subjects.
Category Normal Subjects (n=17) Heroin Users HCV
neg (n=20) Heroin Users HCV
pos (n=17)
Age Mean 6 SD 39.4610.2 38.8612.0 44.1611.3
Range 24–55 22–60 27–62
Gender Male/Female 10/7 13/7 11/6
Race Caucasian/African American/others 8/6/3 10/8/2 7/9/1
doi:10.1371/journal.pone.0009602.t001
CD56
+T Cells in Heroin Use/HCV
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9602excluded if they had major medical or psychiatric disorders. The
demographic data of these subjects are shown in Table 1.
Reagents
Recombinant IL-12 was purchased from R&D Systems Inc.
(Minneapolis, MN). Mouse anti-HCV NS3 antibody was kindly
provided by Dr. Guangxiang Luo (University of Kentucky College of
Medicine, Lexington, KY). The secondary antibodies used for
Western blot (horseradish peroxidase-conjugated goat-anti-rabbit
IgG, goat-anti-mouse IgG, and donkey anti-goat IgG) and Immuno-
fluorescence (FITC-conjugated goat anti–mouse IgG antibody) were
purchased from Jackson ImmunoResearch Laboratories, Inc. (West
Grove, PA) and SouthernBiotech Inc. (Birmingham, AL), respectively.
Isolation of CD56
+ T Cells from PBMCs
PBMCs were isolated from peripheral blood by use of
lymphocyte separation medium (Amersham Pharmacia Biotech)
as described previously [51]. PBMCs were then subjected to
CD56
+ T cell isolation by CD3
+CD56
+ T Cell Isolation Kit
(Miltenyi Biotec, Auburn, CA), in accordance with the manufac-
turer’s instructions. The purity (% of CD3
+CD56
+) of isolated cells
measured by flow cytometry was greater than 95% (Fig. 1).
Purified CD56
+ T cells were then cultured in RPMI 1640
containing 10% fetal bovine serum (HyClone, Logan, UT) and
activated by IL-12 (20ng/mL) for 48h. Cell-free supernatants (SN)
collected from the IL-12-activated CD56
+ T cell cultures were
used as CD56
+ T SN.
Table 2. Primers for Real-Time RT-PCR.
Primer Accession No. Orientation Sequence (59-39) Product Size (bp)
GAPDH NM002046 Sense: GGTGGTCTCCTCTGACTTCAACA 127
Antisense: GTTGCTGTAGCCAAATTCGTTGT
HCV NC004102 Sense: RAYCACTCCCCTGTGAGGAAC 308
NC009823 Antisense: TGRTGCACGGTCTACGAGACCTC
IFN-c NM000619 Sense: AGAAAAATAATGCAGAGCCAAATT 275
Antisense: TGACTCCTTTTTCGCTTCCCTGTT
IL-12Rb1 NM153701 Sense: CCAGGAACCAGACAGAGAAG 151
NM005535 Antisense: TCAGCACCAACCTGGTTATC
IL-12Rb2 NM001559 Sense: ACATTCTTGGACATAGTGAGGCC 80
Antisense: GTACATCTGCTCACGGAAGCC
Jak-2 NM004972 Sense: TTTCGATGGATTTTGCCATT 251
Antisense: GCGAACAGTTTCCATCTGGT
Tyk-2 NM003331 Sense: CTTGACTGTGAACCGGGACT 248
Antisense: TGATGTGCTCGTGGTAGAGC
STAT-1 NM139266 Sense: GTGGAAAGACAGCCCTGCAT 67
NM007315 Antisense: ACTGGACCCCTGTCTTCAAGAC
STAT-3 NM003150 Sense: GGCCCCTCGTCATCAAGA 59
Antisense: TTTGACCAGCAACCTGACTTTAGT
STAT-4 NM003151 Sense: CACCTGCCACATTGAGTCAACTA 72
Antisense: TAAGACCACGACCAACGTACGA
STAT-5a, 5b NM003152 Sense: AGATGCTGGCCGAGGTCAAC 212
NM012448 Antisense: AGACTTGGCCTGCTGCTCAC
SOCS-1 NM003745 Sense: GACGCCTGCGGATTCTACTG 138
Antisense: GGCCATCTTCACGCTAAGGG
SOCS-2 NM003877 Sense: TGCAAGGATAAGCGGACAGG 104
Antisense: CAGAGATGCTGCAGAGATGG
SOCS-3 NM003955 Sense: TGCGCCTCAAGACCTTCAGC 227
Antisense: GATGCGCAGGTTCTTGGTCC
PIAS-1 NM016166 Sense: TCCCACCCAATCTTTGTGTG 380
Antisense: GCCGCATTTTACCAAGTGGA
PIAS-3 NM006099 Sense: TGCTGGCCGGAACAAGAGTG 172
Antisense: AGGGGGCAAAGAGAGAAGGG
PIAS-x (a,b) NM173206 Sense: TCTTCTGACGAAGAGGAAGACC 275
NM004671 Antisense: TCAGAAGATGTTCCAAGCTTCA
PIAS-y NM015897 Sense: GAGAAGAAGCCCACCTGG A 99
Antisense: ACACTCGCTCAGGATCTTCG
doi:10.1371/journal.pone.0009602.t002
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+ T SN Treatment of HCV (JFH-1)-Infected Human
Hepatocytes
The generation of infectious HCV Japanese fulminant
hepatitis-1 (JFH-1) and infection of human hepatocytes (Huh 7
cells) were carried out as previously described [52]. For the
experiments using CD56
+ T SN treatment of hepatocytes
infected with HCV JFH-1, SN was collected and pooled from
IL-12-stimulated CD56
+ T cell cultures of different subjects in
each of the study groups. Pooled CD56
+ T SN from each of the
study groups was added to the hepatocyte cultures at day 3
postinfection and maintained in the cultures for 48h. CD56
+ T
SN-treated hepatocytes were then analyzed by immunofluores-
cent evaluation of HCV NS3 protein expression or by the real-
time RT PCR for HCV RNA quantification. The details of these
assays are described below.
Quantitative Real-Time RT-PCR
Total cellular RNA extraction and the reverse transcription
were performed as described [53]. The real-time RT-PCR for the
quantification of HCV, IFN-c, IL-12 receptor (IL-12Rb1 and IL-
12Rb2), STAT-1, 3, 4, 5, JAK-2, TYK-2, SOCS-1, 2, 3, PIAS-1,
3, x, y and GAPDH mRNA was performed with the iQ SYBR
Green Supermix (Bio-Rad Laboratories, Hercules, CA). The levels
of GAPDH mRNA were used as an endogenous reference to
normalize the quantities of target mRNA. The specific oligonu-
cleotide primers used in this study are listed in Table 2. The
primers were synthesized by Integrated DNA Technologies Inc.
(Coralville, IA).
HCV Viral Load
Total RNA from plasma was extracted with Tri-Reagent-BD
(Molecular Research Center) in accordance with the manufactur-
er’s instructions. The real time RT-PCR assay that we have
developed [15,54] with minor modifications was used for the
quantification of HCV RNA. HCV genome primers used in this
study are listed in Table 2 and the real time RT-PCR was
performed with the iQ SYBR Green Supermix. A standard curve
of HCV was generated with 10-fold dilutions of HCV 59non-
coding region RNA control that had been pre-quantified by a
spectrophotometer (Eppendorf Scientific, Inc. Westbury, NY).
Thermal cycling conditions were designed as follows: initial
denaturation at 95uC for 3 minutes, followed by 40 cycles of
95uC for 10 seconds and 60uC for 1 minute.
Immunoassays
The enzyme-linked immunosorbent assay (ELISA) for IFN-c
was performed according to the protocol provided by the
manufacturer (PBL Biomedical Laboratories, Piscataway, NJ).
Immunofluorescent evaluation of HCV NS3 protein in HCV-
infected hepatocytes was carried out as previously described [53].
Briefly, HCV-infected hepatocytes were fixed with 4% parafor-
maldehyde for 20 min at room temperature on glass coverslips and
then pretreated with a blocking solution for 30 min. The coverslips
were then incubated with anti-NS3 antibody (1:1000) in blocking
solution at room temperature for 60 min and were subsequently
incubated with FITC-conjugated goat anti–mouse IgG antibody
(1:200) for 30 min and Hoechst 33258 (for nuclei) for 15 min. The
coverslips were washed 5 times with 16PBS, mounted in
Vectorshield (Vector Laboratories, Burlingame, CA), and viewed
with a fluorescence microscope (Olympus 1X71 Inverted Micro-
scope, Japan).
Statistical Analysis
Results were expressed as medians or mean 6 standard
deviations and statistically analyzed using Mann-Whitney U-test
or paired Student’s t test (Prism 4.0 software) where appropriate.
Correlations between the IL-12-induced IFN-c by CD56
+ T cells
and the levels of HCV RNA in plasma, or between the levels of
SOCS-3/PIAS-3 in CD56+ T cells and the levels of HCV RNA in
plasma was performed using Spearman’s rank test (Prism 4.0
software). Statistical significance was defined as P,0.05.
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